Lantern Pharma, a clinical-stage biopharmaceutical company, has aligned with industry leaders in declaring the traditional biotech model broken, as discussed at the 2025 BioNTX iC3 Summit. CEO Panna Sharma, who served as moderator and panelist, emphasized the need for technological adoption in drug development processes that remain largely manual. Sharma stated that platforms like Lantern's RADR AI can streamline discovery, accelerate clinical timelines, and reduce costs, directly responding to the summit's call for innovation.
The Dallas Innovates article covering the summit highlighted Sharma's perspective that the industry has been slow to implement available technology that could transform drug development. By advancing a data-driven model, Lantern Pharma positions itself at the forefront of creating a more sustainable future for biotech. The company's approach addresses critical inefficiencies that have long plagued the pharmaceutical industry, particularly in oncology drug development where timelines are extensive and costs are prohibitive.
Lantern Pharma's RADR platform leverages over 200 billion oncology-focused data points and more than 200 machine learning algorithms to accelerate drug discovery and development. This technological capability comes at a crucial time when the industry faces increasing pressure to deliver treatments more efficiently. The full article discussing these developments can be accessed at https://ibn.fm/DM9ur.
The implications of this industry shift toward AI-driven models are significant for patients, healthcare systems, and investors. For cancer patients, accelerated development timelines could mean faster access to potentially life-saving treatments. Healthcare systems may benefit from reduced drug development costs that could translate to more affordable therapies. Investors following Lantern Pharma can find additional updates in the company's newsroom at https://ibn.fm/LTRN.
This movement toward technological transformation in biotech represents a fundamental change in how pharmaceutical companies approach research and development. The traditional model's inefficiencies have resulted in extended timelines and escalating costs that ultimately impact patient access to new treatments. AI-driven platforms offer the potential to identify promising drug candidates more quickly, optimize clinical trial designs, and personalize treatments based on genetic profiles.
The industry-wide recognition of these challenges, as evidenced by the summit discussions, indicates a growing consensus that change is necessary. Lantern Pharma's leadership in this space demonstrates how specialized AI platforms can address specific bottlenecks in oncology drug development. The company's growing pipeline, which includes Phase 2 and Phase 1 clinical programs, showcases the practical application of this technology in advancing treatments for various cancer indications.
